It’s well documented that people with severe mental health conditions such as schizophrenia, suffer from stigmatisation on a regular basis. Stigma can be caused by ignorance or a lack of knowledge about a disease. As the actress Shirley Maclaine once said: Fear makes strangers of people who would be friends. Researchers have developed a number [read the full story…]
We know that many people who take antipsychotic drugs find it difficult to cope with the side effects of the medication and this often leads to them stopping their treatment. This large Finish cohort study examines the risks of rehospitalisation and drug discontinuation in patients recently diagnosed with schizophrenia who have been prescribed antipsychotics. The [read the full story…]
Inpatient psychiatric rehabilitation is needed for about 1% of people with severe mental illnesses such as schizophrenia. Patients are cared for within a rehabilitation centre, sometimes attached to a hospital. The aim is to help these patients recover so that they can be discharged into the community. There is huge variation in the amount of [read the full story…]
First generation typical antipsychotics (e.g. chlorpromazine and haloperidol) have historically been used a great deal to treat people with schizophrenia. More recently, second-generation atypical antipsychotics (e.g. risperidone and olanzapine) have been more frequently used. For many, these drug therapies help to reduce psychotic episodes and the overall impact of the illness, but not all patients [read the full story…]
The British Association for Psychopharmacology regularly publish consensus guidelines on the pharmacological treatment of mental health conditions. In the last two years these publications have included guidance on insomnia (PDF), dementia (PDF) and bipolar disorder (PDF). The latest guideline from the BAP is on the pharmacological treatment of schizophrenia and as usual it’s available in full-text [read the full story…]
People with severe mental illnesses like schizophrenia or bipolar disorder are over three times more likely to lose their teeth because of poor oral health than the general population. The research, published in the September issue of the British Journal of Psychiatry, shows that psychiatric patients have not shared in recent improvements in dental health. [read the full story…]
I’ve blogged before about mental health and smoking cessation, so I was interested to read about this new review on the subject published by a researcher in Spain, which aims to assess the best way for adults with major depression, schizophrenia and psychosis to give up smoking. The review searched a very wide range of [read the full story…]
The PANSS (Positive and Negative Syndrome Scale) is one of the most important rating instruments for patients with schizophrenia. Kay’s original 1987 article on PANSS has been cited more than 4,000 times making it one of the most frequently cited schizophrenia articles on PubMed. Despite its common use there still seems to be profound uncertainty [read the full story…]
This cross-sectional study used a postal questionnaire to find out if there are regional differences in the attitudes of doctors and nurses to antipsychotic polypharmacy and the use of clinical guidelines. A survey was sent to 2 pairs of treatment settings in Denmark, characterized by low and high prevalence of antipsychotic polypharmacy, respectively. The questionnaire [read the full story…]
This year long study carried out by Medical Decision Modeling in Indianapolis set out to measure the cost-effectiveness of the olanzapine long-acting injection with other antipsychotic long-acting injections and oral olanzapine in treating patients with schizophrenia who had trouble adhering to oral drug treatment. The study used a micro-simulation economic decision model to replicate usual care. [read the full story…]
